CompletedPhase 2

Arachidonic Acid Supplementation in Very Preterm Infants

45 participantsStarted 2011-07

Plain-language summary

Long-chain polyunsaturated fatty acids (LCPUFAs), arachidonic acid (AA omega-6; 20:4ω-6), and docosahexaenoic acid (DHA omega-3; 22:6ω-3), are required for the formation of non-myelinated cell membranes in the central nervous system, including in the retina, hence the great importance of them for appropriate visual and cognitive development. In this study, the investigators assessed anthropometric, visual, auditory, and psychomotor development in very preterm infants who had diets supplemented with different LCPUFA amount of AA to support the importance of sufficient AA values in formula.

Who can participate

Age range1 Minute – 2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Living infants who were less than 1500 grams and/or less than 32 weeks gestational age, and whose parents accepted and subscribed the informed consent Exclusion Criteria: * Preterm infants with any severe malformation. * Extremely preterm infants with a gestational age of less than 25 weeks. * Infants whose parents could not complete the follow-up process in our study center. * Preterm infants with severe intraventricular hemorrhage or periventricular leukomalacia (more than grade 2). * Neonates who did not need supplementary milk nutrition, i.e. breastfed-only children.

What they're measuring

Psychomotor development

Timeframe: From september 2013 to november 2014 (at two years of corrected age)

Trial details

NCT IDNCT02503020

SponsorHealth Research Institute of Santiago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-11

View on ClinicalTrials.gov More Impaired Psychomotor Development trials